Abstract | OBJECTIVE: METHODS: Twenty dermatopathologically proven basal cell carcinoma lesions were treated with intralesional IFNalpha-2a injections three times weekly for 3 weeks. The dose per injection was 1.5 x 10(6)IU if the lesion was <2cm in diameter and 3.0 x 10(6) IU if it was >/=2cm. Eight weeks after the last injection, the lesion sites were rebiopsied and all cases were reevaluated both clinically and dermatopathologically. Patients with complete cure were followed up for 7 years to determine the long-term results. RESULTS: Eleven lesions (55%) showed complete clinical and dermatopathological remission, six lesions (30%) showed partial remission, and two lesions (10%) showed no response. One lesion (5%) increased in size during the treatment. No serious adverse effects were observed. During the follow-up period there was only one recurrence, at the fifth year. CONCLUSION: Treatment with intralesional IFNalpha-2a was shown to be an effective therapeutic option for basal cell carcinoma, with low recurrence rates in long-term follow-up.
|
Authors | Seher Bostanci, Pelin Kocyigit, Ayşegül Alp, Cengizhan Erdem, Erbak Gürgey |
Journal | Clinical drug investigation
(Clin Drug Investig)
Vol. 25
Issue 10
Pg. 661-7
( 2005)
ISSN: 1173-2563 [Print] New Zealand |
PMID | 17532711
(Publication Type: Journal Article)
|